美国化学文摘社的动态

CRISPR development is opening new treatment opportunities for genetic disorders that were once deemed untreatable. At Life Edit Therapeutics, we’re propelling CRISPR design and discovery by leveraging artificial intelligence (AI). Learn how we’re expanding therapeutic boundaries in a recent Elevated Insight: https://lnkd.in/eQ32-Pjv. #CRISPR #AI #ElevateBio

The power of AI in life sciences and pharma is revolutionizing the industry, from accelerating drug discovery to advancing gene sequencing. Challenges like integration and security require careful navigation, but the potential for saving lives is immense. Join CXO INSIGHTS hosted by Supermicro and AMD, an exclusive forum for industry leaders to exchange insights on AI-driven transformation. Top executives will discuss leveraging AI for competitiveness, GPU-powered AI in drug development, and collaborative strategies for maximizing AI's value. This invite-only event is tailored for senior executives shaping innovation in healthcare, life sciences, and pharma. Don't miss out on this opportunity to be part of the AI transformation. Apply now: https://lnkd.in/gUF5J7e5 #LifeSciences #PharmaInnovation #HealthcareTech #PrecisionMedicine #DrugDiscovery #AITransformation #AI #GPUComputing #CXOInsights #JPMWeek

Day 1 of 17th Drug Discovery Strategic Summit 2024 kicked off with groundbreaking presentation by Jakob E. Larsen – Director of Drug Discovery Project , Novo Nordisk, delving into their innovative Target Discovery Strategy. Topic : Novo Nordisk’s Target Discovery Strategy – Combining AI/ML, Genetics, and Patient-Centric Approaches. In this session, he explored how Novo Nordisk is revolutionizing drug discovery and development by integrating cutting-edge technologies like Artificial Intelligence and Machine Learning with advanced genetic insights. By taking a patient-centric approach, they aim to not only identify the most promising therapeutic targets but also personalize treatment to improve patient outcomes. Stay Tuned for more updates. #DDSS24 #DDSS24 #DrugDiscovery #BiopharmaInnovation #PharmaEvents #Munich #novonordisk #AI #machinelearning

Tomorrow, Mutlu Dogruel will be attending the Functional genomic screens and AI: a key partnership for successful therapeutic development event hosted by the Cambridge Network and Milner Therapeutics in Cambridge. If you're attending, reach out to Mutlu to learn more about Cresset's AI insights and capabilities. #drugdiscovery #drugdesign #smallmolecule #compchem #AI

An exciting #Digitalpathology update from here in the UK! Histofy introduce their new AI Toolset, GI-miner which will transform GI pathology ?? https://lnkd.in/gPcUmCHY

Deepmind's AlphaFold 3 can predict how DNA, RNA, and other molecules interact. This paves the way to accelerated drug discovery, scientific research, and clinical studies. #Strategy #TechStrategy #AI #LifeSciences #Deepmind

We are excited to introduce GI-Miner??? GI-Miner is a powerful AI toolset that extracts measurable and interpretable features to enable deep profiling of GI tissue images. ? Key Highlights ? ? Cutting-Edge AI:?Uses advanced machine learning to identify key cell types and histological structures. ? Pathologist-Friendly Features: Extracts a rich set of interpretable features to enhance GI research. ? Biomarker Discovery: Improves patient stratification, advancing biopharma and drug development. ??Unlock insights to advance GI research, accelerate drug discovery and drive breakthroughs in personalised medicine. ?? Learn more about GI-Miner: https://lnkd.in/gPcUmCHY ?? Book a demo: https://lnkd.in/ghAkrkSR #Histofy #GIMiner #AIinHealthcare #BiomarkerDiscovery

A true essence of a CAD software development for Computational Pathology led by Professor Nasir Rajpoot. This is what we have been highlighting in our recent survey paper from JPI (https://lnkd.in/dDmwWAQ9) that despite many AI developments in pathology, the CAD software integration in clinical pathology has not been triggered properly yet. GI-Miner can be among very few that I think it can make such pathway. Great kudos to you Dr. Rajpoot and the Histofy team!

Gauntlet thrown: A competition to use unpublished NGS data to design improved antibodies. This is similar in concept to the CASP protein folding competitions, but in this case the new designs submitted will be made and experimentally tested to identify the best way(s) to do in silico antibody development informed by large sequencing datasets.

TamGen, a novel generative AI framework, accelerates drug discovery, especially antibiotic development, by combining deep learning and molecular dynamics simulations to predict molecule-target interactions. This innovative approach is part of a broader trend using AI in healthcare, exemplified by other AI models focused on drug discovery for various diseases, including cancer. These AI advancements significantly impact the drug development process by efficiently exploring chemical possibilities. The urgent need for new antibiotics to fight drug-resistant bacteria is a key driver for this technological progress. Ultimately, these AI tools aim to expedite the creation of effective new medications. https://lnkd.in/dwarmBM8